Kallikrein相关肽酶：对癌症潜在治疗靶向的机械理解
Kallikrein-related peptidases: mechanistic understanding for potential therapeutic targeting in cancer
影响因子:4.40000
分区:医学2区 / 药学2区
发表日期:2024 Oct
作者:
Glykeria N Daneva, Panagiotis Tsiakanikas, Panagiotis G Adamopoulos, Andreas Scorilas
摘要
与人类Kallikrein相关的肽酶（KLK）代表了15种丝氨酸内肽酶的亚组，其中包括包括癌症，包括癌症。这一综述旨在对KLK家族进行全面的概述，强调其基因组结构，表达谱和鉴定物的特定性。我们探讨了KLK在肿瘤发生中的作用，强调了它们作为生物标志物和治疗靶标在癌症治疗中的潜力。 KLK的活性失调与各种恶性肿瘤有关，使它们有望接受癌症诊断和治疗。：了解与KLK相关肿瘤的机械途径的最新进步为开发靶向癌症治疗提供了新的前景。专家意见表明，尽管已经取得了重大进展，但对于完全利用KLK在临床应用中的潜力中，需要进一步的研究。
Abstract
Human kallikrein-related peptidases (KLKs) represent a subgroup of 15 serine endopeptidases involved in various physiological processes and pathologies, including cancer.This review aims to provide a comprehensive overview of the KLK family, highlighting their genomic structure, expression profiles and substrate specificity. We explore the role of KLKs in tumorigenesis, emphasizing their potential as biomarkers and therapeutic targets in cancer treatment. The dysregulated activity of KLKs has been linked to various malignancies, making them promising candidates for cancer diagnostics and therapy.: Recent advancements in understanding the mechanistic pathways of KLK-related tumorigenesis offer new prospects for developing targeted cancer treatments. Expert opinion suggests that while significant progress has been made, further research is necessary to fully exploit KLKs' potential in clinical applications.